Closing The Books On GDUFA II: How Generics Fared At US FDA Over The Last Five Years
Approval and submission data indicate steady trends aside from one outlier year.
You may also be interested in...
Several fees for prescription drug, generic drug, and biosimilar applications are set to increase, although some also will drop.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
CBER Director Peter Marks said more sophisticated manufacturing expected in the next decade could lead to questions about whether gene therapies should be regulated by his center or CDRH.